GenoMed, Inc. Adds Jason Moore, Ph.D., to its Scientific Advisory Board
January 21, 2002--GenoMed Inc.--(“the Company” or “GenoMed”) (National Quotation Bureau’s Pink Sheets Symbol: GMED) a St. Louis, Missouri based medical genomics biotechnology company, announced today the appointment of Dr. Jason Moore to the Company’s Scientific Advisory Board.
Dr. Moore received his training in Applied Statistics (M.A.) and Human Genetics (M.S., Ph.D.) at the University of Michigan with a focus on the genetic epidemiology of common, complex diseases such as hypertension and cardiovascular disease. Now an Assistant Professor in the Program in Human Genetics at Vanderbilt University Medical School, Dr. Moore has established himself as a leader in the development and application of cutting-edge statistical and computational methods for identifying genes that influence risk of common diseases only through complex interactions with other genes and environmental factors.
Dr. Moore recently received the 2001 James V. Neel Young Investigator award from the International Genetic Epidemiology Society in connection with his work in this area. His current work includes the development of the Multifactor Dimensionality Reduction (MDR) approach that was used in the first study to demonstrate interactions between more than three single-nucleotide polymorphisms in a common, complex human disease – sporadic breast cancer. The development of machine learning and pattern recognition approaches such as MDR and the establishment of a 110-processor supercomputer have positioned Dr. Moore to lead efforts to identify combinations of single-nucleotide polymorphisms from among thousands of candidates that predict risk of common disease such as hypertension, cardiovascular disease, cancer, depression, and diabetes.
GenoMed's Chairman, Dr. David Moskowitz, stated that, "We are extremely pleased that Dr. Moore, who is already among the elite of genetic statisticians, has agreed to join our Scientific Advisory Board. His development of statistically robust methods to find disease-associated genes is a tremendously valuable contribution to the field of human genetics. His expertise fits extremely well with the methods we are using to locate disease genes.”
About GenoMed
GenoMed was founded with the sole purpose of translating knowledge of disease genomics into improved patient treatments. The Company is screening millions of genotypes for association with various diseases in an effort to identify novel therapeutic targets for existing prescription drugs. GenoMed expects to generate revenues by licensing its discoveries to the pharmaceutical industry for the expansion of drug labels and early diagnosis of disease. The Company has already filed initial patent applications with the United States Patent and Trademark Office that substantiate improved patient outcomes in pilot trials.
For additional information please visit genomedics.com and/or contact Craig Hall @ (941) 366-6677 or email at chall@floridafunds.com for a GenoMed investor package.
. |
